Loading Complete
Shenhong Wu, MD, PhD
Medical Oncology
Accepting New Patients
Video Visit
Need help scheduling? Call 631-638-1000
Highlights
Languages
- Chinese - Mandarin
- English
Gender
MaleAbout Shenhong Wu
About
Clinical care and research for patients with cancer of prostate, bladder, kidney and testis is the primary focus of my practice.
Academic Title
Clinical Associate Professor of Medicine
Publications
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR | Benhuri B | Postow MA | Hellmann MD | Lesokhin AM | Segal NH | Motzer RJ | Wu S | Busam KJ | Wolchok JD | Lacouture ME
European journal of cancer (Oxford, England : 1990)
2016 Mar 31 - Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR | Serna-Tamayo C | Wu S | Lacouture ME
Clinical and experimental dermatology
2016 Jan - The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis.
Capriotti K | Capriotti JA | Lessin S | Wu S | Goldfarb S | Belum VR | Lacouture ME
The British journal of dermatology
2015 Sep - Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.
Shameem R | Hamid MS | Xu KY | Wu S
World journal of clinical oncology
2015 Aug 10 - Reply to: Skin moisturization for xerosis related to targeted anticancer therapies.
Valentine J | Belum VR | Duran J | Ciccolini K | Schindler K | Wu S | Lacouture ME
Journal of the American Academy of Dermatology
2015 Jul - Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R | Hamid MS | Wu S
Anticancer research
2015 Apr - Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J | Belum VR | Duran J | Ciccolini K | Schindler K | Wu S | Lacouture ME
Journal of the American Academy of Dermatology
2015 Apr - Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R | Lacouture M | Wu S
Cancer investigation
2015 Mar - Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma.
Xu KY | Wu S
Biomarker research
2015 - Alopecia in patients treated with molecularly targeted anticancer therapies.
Belum VR | Marulanda K | Ensslin C | Gorcey L | Parikh T | Wu S | Busam KJ | Gerber PA | Lacouture ME
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2015 Dec - Novel therapy for advanced gastric cancer.
Zhang Y | Wu S
World journal of gastrointestinal oncology
2015 Nov 15 - Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R | Lacouture M | Wu S
Acta oncologica (Stockholm, Sweden)
2015 Jan - Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
Ramirez-Fort MK | Case EC | Rosen AC | Cerci FB | Wu S | Lacouture ME
American journal of clinical oncology
2014 Jun - Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.
Spratt DE | Gordon Spratt EA | Wu S | DeRosa A | Lee NY | Lacouture ME | Barker CA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014 Oct 1 - The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
Minkis K | Garden BC | Wu S | Pulitzer MP | Lacouture ME
Journal of the American Academy of Dermatology
2013 Sep - Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Kapadia S | Hapani S | Choueiri TK | Wu S
Acta oncologica (Stockholm, Sweden)
2013 Aug - Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Nardone B | Wu S | Garden BC | West DP | Reich LM | Lacouture ME
Clinical lymphoma, myeloma & leukemia
2013 Aug - Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR | Wu S | Lacouture ME
Investigational new drugs
2013 Aug - The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
Fischer A | Wu S | Ho AL | Lacouture ME
Investigational new drugs
2013 Jun - Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A | Rosen AC | Ensslin CJ | Wu S | Lacouture ME
Dermatologic therapy
2013 Mar-Apr - Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
Drucker AM | Wu S | Busam KJ | Berman E | Amitay-Laish I | Lacouture ME
European journal of haematology
2013 Feb - The efficacy of temozolomide for recurrent glioblastoma multiforme.
Chen C | Xu T | Lu Y | Chen J | Wu S
European journal of neurology : the official journal of the European Federation of Neurological Societies
2013 Feb - Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
Ensslin CJ | Rosen AC | Wu S | Lacouture ME
Journal of the American Academy of Dermatology
2013 Nov - Alopecia with endocrine therapies in patients with cancer.
Saggar V | Wu S | Dickler MN | Lacouture ME
The oncologist
2013 - The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Garden BC | Wu S | Lacouture ME
Journal of the American Academy of Dermatology
2012 Sep - Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM | Wu S | Dang CT | Lacouture ME
Breast cancer research and treatment
2012 Sep - The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Balagula Y | Wu S | Su X | Feldman DR | Lacouture ME
Investigational new drugs
2012 Aug - Anticancer therapy-induced adverse events: practicing damage control.
Lacouture ME | Lenihan D | Wu S
Expert opinion on drug safety
2012 May - Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Rosen AC | Wu S | Damse A | Sherman E | Lacouture ME
The Journal of clinical endocrinology and metabolism
2012 Apr - The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
Gomez-Fernandez C | Garden BC | Wu S | Feldman DR | Lacouture ME
European journal of cancer (Oxford, England : 1990)
2012 Feb - Controversial role of bevacizumab in the development of venous thromboembolic events.
Hapani S | Wu S
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2011 Sep 1 - Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Wu S | Keresztes RS
Cancer investigation
2011 Aug - Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
Chen T | Xu T | Li Y | Liang C | Chen J | Lu Y | Wu Z | Wu S
Cancer treatment reviews
2011 Jun - Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Kollmannsberger C | Bjarnason G | Burnett P | Creel P | Davis M | Dawson N | Feldman D | George S | Hershman J | Lechner T | Potter A | Raymond E | Treister N | Wood L | Wu S | Bukowski R
The oncologist
2011 - Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V | Hapani S | Wu S
JAMA : the journal of the American Medical Association
2011 Feb 2 - The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.
Balagula Y | Wu S | Su X | Lacouture ME
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2011 Nov - Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A | Wu S
Acta oncologica (Stockholm, Sweden)
2011 Oct - Inverse association between eczema and meningioma: a meta-analysis.
Wang M | Chen C | Qu J | Xu T | Lu Y | Chen J | Wu S
Cancer causes & control : CCC
2011 Oct - Bevacizumab increases risk for severe proteinuria in cancer patients.
Wu S | Kim C | Baer L | Zhu X
Journal of the American Society of Nephrology : JASN
2010 Aug - Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V | Pulipati B | Chu D | Zhu X | Wu S
American journal of hypertension
2010 May - Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V | Hapani S | Chuang J | Wu S
Acta oncologica (Stockholm, Sweden)
2010 Apr - Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report.
Hapani S | Chu D | Wu S
Journal of medical case reports
2010 - Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
Hapani S | Sher A | Chu D | Wu S
Oncology
2010 - Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X | Lacouture ME | Jia Y | Wu S
Oncology
2009 - Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Hapani S | Chu D | Wu S
The lancet oncology
2009 Jun - Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A | Wu S | Jia Y | Agulnik M | Millender L | Lacouture ME
Cancer
2009 Mar 15 - Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y | Lacouture ME | Su X | Wu S
The journal of supportive oncology
2009 Nov-Dec - Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D | Lacouture ME | Weiner E | Wu S
Clinical genitourinary cancer
2009 Jan - Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Zhu X | Stergiopoulos K | Wu S
Acta oncologica (Stockholm, Sweden)
2009 - Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lacouture ME | Wu S | Robert C | Atkins MB | Kong HH | Guitart J | Garbe C | Hauschild A | Puzanov I | Alexandrescu DT | Anderson RT | Wood L | Dutcher JP
The oncologist
2008 Sep - Novel therapies in genitourinary cancer: an update.
Chu D | Wu S
Journal of hematology & oncology
2008 - Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
Rosenbaum SE | Wu S | Newman MA | West DP | Kuzel T | Lacouture ME
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
2008 Jun - Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S | Chen JJ | Kudelka A | Lu J | Zhu X
The lancet oncology
2008 Feb - Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR | Chu D | Keresztes R | Zhu X | Wu S
JAMA : the journal of the American Medical Association
2008 Nov 19 - Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Chu D | Lacouture ME | Fillos T | Wu S
Acta oncologica (Stockholm, Sweden)
2008 - Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Gulley JL | Wu S | Arlen PM | Dahut WL
Clinical genitourinary cancer
2007 Sep - The use of bisphosphonates in cancer patients.
Wu S | Dahut WL | Gulley JL
Acta oncologica (Stockholm, Sweden)
2007 - Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Figg WD | Li H | Sissung T | Retter A | Wu S | Gulley JL | Arlen P | Wright JJ | Parnes H | Fedenko K | Latham L | Steinberg SM | Jones E | Chen C | Dahut W
BJU international
2007 May - Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone.
Wu SL | Jones E | Gulley JL | Arlen PM | Chen CC | Figg WD | Dahut WL
BJU international
2007 Mar - Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X | Wu S | Dahut WL | Parikh CR
American journal of kidney diseases : the official journal of the National Kidney Foundation
2007 Feb
Locations
- Stony Brook Cancer Center - Medical Oncology
- Lauterbur Drive, Stony Brook, NY 11794
- Get Directions
- phone: 631-638-1000
- fax: 631-638-0915
- The Phillips Family Cancer Center - Medical Oncology Provider
- 740 County Road 39A, Southampton, NY 11968
- Get Directions
- phone: 631-638-7702
- fax: 631-638-7327
Expertise
Education
- Fellowship: National Institutes of Health Clinical Center, IM-Oncology, 2006
- Residency: Bridgeport Hospital (Yale Univ School of Medicine), Internal Medicine, 2004
- Post Doctoral Fellow: University of Chicago Division of the Biological Sciences The Pritzker School of Medicine, Pathology, 2001
- Doctoral Program: Medical College of Wisconsin, 1996
- Post Graduate: Shanghai Medical University, Surgery, 1990
- Medical School: Wenzhou Medical Collge, 1987
Insurance
Please contact the doctor's office directly to confirm acceptance of insurance.
Search plans
- (Anthem) EMP HEALTH CHOICE HMO
- (Anthem) EMP HEALTH CHOICE MEDICAID
- (Anthem) EMP HEALTH CHOICE SR
- (Emblem) HIP
- AETNA
- Affinity
- Beech Street/Multiplan/PHCS
- Centerlight (CCM)
- CIGNA PPO
- Fidelis
- GHI / MEDICARE PLUS
- GHI CBP
- Health Smart WTC
- HEALTHFIRST
- Humana Military
- MAGNACARE
- MET EMPIRE
- OXFORD
- Partners Health Plan
- Sedgwick
- UNITED HEALTH CARE / CHP / MEDICAID
- UNITED HEALTHCARE
- Workers Compensation
